Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  17 (2025)
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 17 , ISSUE 1 ( January-February, 2025 ) > List of Articles

RESEARCH ARTICLE

Placental Growth Factor and Adverse Obstetric Outcomes in Women Screened in the First Trimester of Pregnancy: A Prospective Cohort Study

Ashima Taneja, Mehak Arora, Swati Jain, Surbhi Handa, Janvi Singla, Baljinder Kaur, Romi Jindal, Namita Bansal

Keywords : Adverse maternal outcome, Adverse neonatal outcome, Biomarker, Placental growth factor, Prediction, Pregnancy, Screening

Citation Information : Taneja A, Arora M, Jain S, Handa S, Singla J, Kaur B, Jindal R, Bansal N. Placental Growth Factor and Adverse Obstetric Outcomes in Women Screened in the First Trimester of Pregnancy: A Prospective Cohort Study. J South Asian Feder Obs Gynae 2025; 17 (1):5-9.

DOI: 10.5005/jp-journals-10006-2565

License: CC BY-NC 4.0

Published Online: 28-03-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Objective: To study association of first trimester levels of placental growth factor (PIGF) and adverse obstetric outcomes. Methods: This study was done at a tertiary center of North India between March 2022 and 2023 on singleton pregnant females. Multiple and molar pregnancies, smokers, and patients with chronic hypertension were excluded. It was a prospective study. A total of 180 women were included. Samples for PlGF were collected between 11 and 13 weeks of pregnancy. These patients were followed till delivery. Their obstetric and perinatal outcome was correlated with the levels of PlGF. Results: Patients showing low PlGF had statistically significant adverse maternal outcomes like maternal death, eclampsia, HELLP, pulmonary edema, abruption, postpartum hemorrhage, cesarean section, preeclampsia with a p-value of 0.020. The composite fetal adverse outcomes like intrauterine death, SGA, respiratory distress syndrome, necrotizing enterocolitis, intraventricular hemorrhage, NICU admission was also statistically significant in low PlGF group (p-value 0.023). PlGF was 67.31% sensitive and 42.31% specific for maternal adverse outcomes. For fetal adverse outcomes the sensitivity and specificity were 52.94% and 69.12% respectively. Conclusion: Placental growth factor can be used as a predictor for adverse pregnancy outcome.

PDF Share
  1. Khan B, Allah Yar R, Khakwani AK, et al. Preeclampsia incidence and its maternal and neonatal outcomes with associated risk factors. Cureus 2022; 14(11):e31143. DOI: 10.7759/cureus.31143.
  2. Nankali A, Malek-Khosravi, Zangeneh M, et al. Maternal complications associated with severe preeclampsia. J Obstet Gynaecol India 2013; 63(2):112–115. DOI: 10.1007/s13224-012-0283-0.
  3. Sirenden H, Sunarno I, Arsyad MA, et al. Birth weight, Apgar score, and fetal complications in mothers with severe preeclampsia. Enfermeria clinica 2020;30:533–536. DOI:10.1016/j.enfcli.2019.07.154
  4. Salem MAA, Ammar IMM. First-trimester uterine artery pulsatility index and maternal serum PAPP-A and plgf in prediction of preeclampsia in primigravida. J Obstet Gynaecol India 2018; 68:192–196. DOI: 10.1007/s13224-017-1012-5.
  5. Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens 2017;31:782–786. DOI: 10.1038/jhh.2017.61.
  6. Serra B, Mendoza M, Scazzocchio E, et al. A new model for screening for early-onset preeclampsia. Am J Obstet Gynecol 2020;222(6):608.e1–e608.e18. DOI: 10.1016/j.ajog.2020.01.020.
  7. Prasad S, Sahota DS, Vanamail P, et al. Performance of Fetal Medicine Foundation algorithm for first trimester preeclampsia screening in an indigenous south Asian population. BMC Pregnancy Childbirth 2021;21(1):805. DOI: 10.1186/s12884-021-04283-6.
  8. Wright D, Syngelaki A, Akolekar R, et al. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015; 213(1):62.e1–62.e10. DOI: 10.1016/j.ajog.2015.02.018.
  9. Morris RK, Bilagi A, Devani P, et al. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: Systematic review and meta-analysis. Prenat Diagn 37(3):253–265. DOI: 10.1002/pd.5001.
  10. Odibo AO, Patel KR, Spitalnik A, et al. Placental pathology, first trimester biomarkers and adverse pregnancy outcomes. J Perinatol 2014;34(3):186–191. DOI: 10.1038/jp.2013.176.
  11. Allen R, Aquilina J. Prospective observational study to determine the accuracy of first trimester serum biomarkers and uterine artery Dopplers in combination with maternal characteristics and arteriography for the prediction of women at risk of preeclampsia and other adverse pregnancy outcomes. J Matern Fetal Neonatal Med 2018; 31(21):2789–2806. DOI: 10.1080/14767058.2017.1355903.
  12. Ekelund CK, Rode L, Tabor A, et al. Placental growth factor and adverse obstetric outcomes in a mixed-risk cohort of women screened for preeclampsia in the first trimester of pregnancy. Fetal Diagn Ther 2021;48(4):304–312. DOI: 10.1159/000514201.
  13. Mendoza M, Tur H, Garcia-Manau P, et al. Cut-off values for Gaussian first-trimester screening for early-onset preeclampsia with maternal history, biochemical markers and uterine artery Doppler. J Gynecol Obstet Hum Reprod 2021;50(1):101827. DOI: 10.1016/j.jogoh.2020.101827.
  14. Hayes-Ryan D, Khashan AS, Hemming K, et al. PARROT Ireland trial group. Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: A stepped wedge cluster randomised control trial (PARROT Ireland). BMJ 2021;374:n1857. DOI: 10.1136/bmj.n1857.
  15. Balyan K, Humtso BY, Meena B, et al. Materno-fetal outcome with PlGF above or below cutoff during second half of pregnancy in high-risk women. Int J Gynecol Obstet 2024;165(1):211–219. DOI: 10.1002/ijgo.15143.
  16. Creswell L, O'Gorman N, Palmer KR, et al. Perspectives on the use of placental growth factor (PlGF) in the prediction and diagnosis of pre-eclampsia: Recent insights and future steps. Int J Womens Health 2023;13:15:255–271. DOI: 10.2147/IJWH.S368454.
  17. Bdolah Y, Elchalal U, Natanson-Yaron S, et al. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy 2014;33(2):250–259. DOI: 10.3109/10641955.2013.858745.
  18. Steegers EA, Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet 2010;376(9741):631–644. DOI: 10.1016/S0140-6736(10)60279-6.
  19. Saleh L, Vergouwe Y, Meiracker AH, et al. Angiogenic markers predict pregnancy complications and prolongation in preeclampsia: Continuous versus cutoff values. Hypertension 2017;70(5):1025–1033. DOI: 10.1161/HYPERTENSIONAHA.117.09913.
  20. Neuman RI, Saleh L, Verdonk K, et al. Accurate prediction of total PlGF (placental growth factor) from free PlGF and sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1): Evidence for markedly elevated PlGF levels in women with acute fatty liver of pregnancy. Hypertension 2021;78(2):489–498. DOI: 10.1161/HYPERTENSIONAHA.121.17258.
  21. Parchem JG, Brock CO, Chen HY, et al. Placental growth factor and the risk of adverse neonatal and maternal outcomes. Obstet Gynecol 2020;135(3):665–673. DOI: 10.1097/AOG.0000000000003694.
  22. Griffin M, Seed PT, Duckworth S, et al. Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia. Ultrasound Obstet Gynecol 2018;51(3):304–305. DOI: 10.1002/uog.19017.
  23. McLaughlin K, Snelgrove JW, Audette MC, et al. PlGF (Placental Growth Factor) testing in clinical practice: Evidence from a Canadian Tertiary Maternity Referral Center. Hypertension 2021;77:2057– 2065. DOI: 10.1161/HYPERTENSIONAHA.121.17047.
  24. Spencer R, Maksym K, Hecher K, et al. Maternal PlGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction. J Clin Invest 2023;133(18):e169199. DOI: 10.1172/JCI169199.
  25. Sherrell H, Dunn L, Clifton V, et al. Systematic review of maternal placental growth factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes. Eur J Obstet Gynecol Reprod Biol 2018;225:26–34. DOI: 10.1016/j.ejogrb.2018. 03.059.
  26. Duhig KE, Seed PT, Myers JE, et al. Placental growth factor testing for suspected pre-eclampsia: A cost-effectiveness analysis. BJOG 2019;126(11):1390–1398. DOI: 10.1111/1471-0528.15855.
  27. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and prediction. Am J Obstet Gynecol 2022;226(2S):S1071–S1097.e2. DOI: 10.1016/j.ajog.2020.07.020.
  28. Hurrell A, Webster L, Sparkes J, et al. PARROT-2 trial group. Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): A multicentre, parallel-group, superiority, randomised controlled trial. Lancet 2024;403(10427):619–631. DOI:10.1016/S0140-6736(23)02357-7.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.